[1] Bindom SM, Lazartigues E.The sweeter side of ACE2: physiological evidence for a role in diabetes[J]. Mol Cell Endocrinol, 2009, 302(2): 193-202. [2] Moon JY, Jeong KH, Lee SH, et al.Renal ACE and ACE2 expression in early diabetic rats[J]. Nephron Exp Nephrol,2008, 110(1): e8-e16. [3] 董殿军, 郭秀云. 番茄红素的生理学作用与机制的研究进展[J]. 中国慢性病预防与控制, 2006, 14(3):220-222. [4] 林善锬. 糖尿病肾病[J]. 中华内科杂志, 2005, 44(3):229-231. [5] Zhuo JL, Li XC.New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensinⅡ[J]. Peptides, 2011, 32(7):1551-1565. [6] Carey RM, Siragy HM.Newly recognized components of the rennin angiotensin system: potential roles in cardiovascular and renal regulation[J]. Endocrine Reviews, 2003, 24(3):261-271. [7] Wolf G.New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology[J]. Eur J Clin Invest, 2004, 34(12), 785-796. [8] Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy[J]. Hypertension, 2003, 41(3): 392-397. [9] Liu CX, Hu Q, Wang Y, et al.Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition[J]. Mol Med, 2011, 17(1-2): 59-69. [10] BürgelováM, Kramer HJ, Teplan V, et al. Effects of angiotensin-(1-7) blockade on renal function in rats with enhanced intrarenal AngⅡactivity[J]. Kidney Int, 2005, 67(4):1453-1461. |